Summit Corporation plc
("Summit plc" or "the Company")
Oxford, UK, 2 April 2008 - Summit Corporation plc (AIM: SUMM) notifies the market of the following information in order to conform to 5.6.1 of the Disclosure and Transparency rules:
The issued share capital consists of 50,841,660 ordinary shares of 10p each with voting rights. No ordinary shares are held in treasury.
The above figure of 50,841,660 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.
The above figure of 50,841,660 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.
- ENDS -
For more information, please contact:
Summit plc
Darren Millington, ACMA, Chief Financial Officer
Richard Pye, PhD, Investor Relations
Darren Millington, ACMA, Chief Financial Officer
Richard Pye, PhD, Investor Relations
Tel: +44 (0)1235 443951
Panmure Gordon
Andrew Burnett / Rakesh Sharma
Andrew Burnett / Rakesh Sharma
Tel: +44 (0)207 459 3600
About Summit plc
Summit plc is a leading UK biotechnology company that discovers and develops proprietary new drugs. The Company's internal drug development programmes are underpinned by its advanced carbohydrate chemistry and zebrafish drug screening technology platforms, which it also provides on a collaborative or fee-for-service basis to the pharmaceutical industry.
Summit plc has a broad range of drug discovery programmes in the clinical, pre-clinical and discovery stages of development, which target serious diseases with a high unmet medical need. These therapeutic areas include neurological disorders, anti-infectives, ophthalmic diseases and oncology.
Summit plc's in-house drug development capabilities combine world-class expertise in both carbohydrate chemistry with high-volume, high-content screening using its proprietary zebrafish technologies. These whole organism screens have the potential to dramatically decrease the time and cost of drug discovery and development by delivering data that are highly predictive of the efficacy and toxicity of potential drug compounds in humans.
The company listed on the AIM market of the London Stock Exchange in October 2004 - symbol: SUMM
Further information about the company is available at www.summitplc.com